News

05/10/2021 - General information

Hospital del Mar and IMIM to participate in the new CIBER on infectious diseases

With this new group, the Carlos III Health Institute's Networked Biomedical Research Centre aims to unite Spain's scientific excellence in this field to enable better funding in emerging diseases, such as COVID-19, and other research areas, including antimicrobial resistance and HIV-AIDS, in which Hospital del Mar and IMIM researchers have a great deal of experience.

The Infectious Pathology and Antimicrobial Research Group (IPAR) at the Hospital de Mar Medical Research Institute (IMIM) will form part of the new CIBER on Infectious Diseases. The purpose of this new group is to promote research in this field in Spain by offering new structural funding tools.

Servei_Malalties_Infeccioses

Membres del Servei de Malalties Infeccioses

The key areas the new CIBER will be involved in are emerging infectious diseases, such as COVID-19, and priority lines of research for the Carlos III Health Institute and the National Health System, which are promoting this CIBER initiative. The main thrust involves the question of antimicrobial resistance and HIV-AIDS, among others.

Dr. Juan Pablo Horcajada, head of the Infectious Diseases Service at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the IMIM, emphasises that the inclusion of the group in the new CIBER means "an important step forward as we are recognised as one of the groups of excellence in terms of infectious disease research in Spain, and it gives us an opportunity to initiate and consolidate more collaborations with other leading groups." The research group, also recognised by the Agency for the Management of University and Research Grants (AGAUR), has, since 2016, been part of the Spanish Network for Research into Infectious Diseases (REIPI), as well as several groups of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

Within the new CIBER on Infectious Diseases the group will focus on antimicrobial resistance, hospital infections (in which it is a leader in Spain), studies of the pharmacokinetics and pharmacodynamics of antimicrobials, AIDS and inflammation, and infection by COVID-19 and other infections with the capacity to cause epidemics and pandemics.

More news